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There has been intense debate over the immunological 
basis of schizophrenia, and the potential utility of adjunct 
immunotherapies. The major histocompatibility complex 
is consistently the most powerful region of association in 
genome-wide association studies (GWASs) of schizophrenia 
and has been interpreted as strong genetic evidence support-
ing the immune hypothesis. However, global pathway analy-
ses provide inconsistent evidence of immune involvement in 
schizophrenia, and it remains unclear whether genetic data 
support an immune etiology per se. Here we empirically 
test the hypothesis that variation in immune genes contrib-
utes to schizophrenia. We show that there is no enrichment 
of immune loci outside of the MHC region in the largest 
genetic study of schizophrenia conducted to date, in contrast 
to 5 diseases of known immune origin. Among 108 regions 
of the genome previously associated with schizophrenia, 
we identify 6 immune candidates (DPP4, HSPD1, EGR1, 
CLU, ESAM, NFATC3) encoding proteins with alterna-
tive, nonimmune roles in the brain. While our findings do 
not refute evidence that has accumulated in support of the 
immune hypothesis, they suggest that genetically mediated 
alterations in immune function may not play a major role in 
schizophrenia susceptibility. Instead, there may be a role for 
pleiotropic effects of a small number of immune genes that 
also regulate brain development and plasticity. Whether 
immune alterations drive schizophrenia progression is an 
important question to be addressed by future research, 
especially in light of the growing interest in applying immu-
notherapies in schizophrenia.
Key words:  schizophrenia/genetic/immune/inflammation/
autoimmune/inflammatory
Introduction
Schizophrenia is a severe psychiatric disease that disturbs 
multiple aspects of mental function. Although its etiol-
ogy remains poorly understood, liability is largely geneti-
cally mediated.1 In the largest genome-wide association 
study (GWAS) yet conducted (n  =  35 476 cases, 46 839 
controls), over 100 independent loci were robustly associ-
ated with the disease.2 This GWAS represents a signifi-
cant advance towards defining the molecular parts list for 
schizophrenia, and provides an opportunity to integrate 
genetic information with existing biological data to test 
specific etiological hypotheses.
Among many hypotheses of schizophrenia etiology, the 
longstanding immune theory posits that dysregulation of 
the immune system causes schizophrenia in at least a sub-
set of patients.3–6 It is known that immune components 
such as MHC class I,7 TNF-α,8 complement,9 TGF-β,10 
and IL-611 regulate brain development and adult neural 
plasticity. Exposure to the wrong level of an immune fac-
tor at the wrong time may consequently disrupt brain 
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development and adult neural functioning, as supported 
by in utero immune activation in rodents12 and primates.13 
Many schizophrenia patients show hallmarks of immune 
disease—such as prior infection,14 presence of autoan-
tibodies,15 co-occurring autoimmunity,16 and inflamma-
tion,17,18—supporting the idea that immune disturbances 
may play a role in schizophrenia by disrupting brain 
development and/or adult neural function.
Given the immune disturbances apparent among schizo-
phrenia patients, there is considerable interest in treating 
the disease with immune-modulating drugs.19 Non-specific 
anti-inflammatory agents (eg, aspirin) have shown modest 
efficacy among schizophrenia patients,20 and randomized 
controlled trials with more targeted immunotherapies (eg, 
Tocilizumab, a monoclonal antibody against the IL-6 recep-
tor)21 are currently underway. Importantly, the underlying 
cause of immune perturbation in schizophrenia remains 
unknown. A  combination of genetic and environmental 
risk factors has been proposed to initiate immune abnor-
malities among patients with schizophrenia.22 Alternatively, 
the immune disturbances may be epiphenomena driven 
by disease pathogenesis, exposure to antipsychotic drugs, 
or lifestyle factors associated with schizophrenia such as 
smoking. Immune profiling studies of schizophrenia have 
primarily been cross-sectional in nature, precluding causal 
inferences. Furthermore, important factors influencing 
immune status—such as hospitalization, age, sex, body 
mass index, diet, smoking, and medication use23—are asso-
ciated with schizophrenia case status23 and are not always 
accounted for. Thus, it remains unclear from the existing 
literature whether the relationship between schizophrenia 
and immune disturbances is causal, correlative, or an epi-
phenomenon. Adjunct immunotherapy may be a viable 
therapeutic option regardless of the role of immune dys-
regulation—whether it causes schizophrenia, influences 
disease progression, or is a biomarker for disease. However, 
clarifying the role of immune processes in schizophrenia 
has important implications for understanding disease biol-
ogy, optimizing the timing of immunotherapy interven-
tions, and developing effective targeted therapies.
If  genetic variants influencing immune function were 
associated with elevated risk of schizophrenia, this would 
provide strong evidence that immune abnormalities are 
causal drivers of disease. Although genetic data have 
been interpreted as supporting immune involvement,22,24,25 
largely due to the strong association of single-nucleotide 
polymorphism (SNP) alleles in the extended major histo-
compatibility complex (xMHC),24 previous studies have 
reported conflicting results with respect to immune path-
way involvement. For instance, in gene set enrichment 
analysis of the Genetic Association Information Network 
(GAIN) schizophrenia GWAS (1158 cases and 1378 con-
trols), 3 of the 7 overrepresented pathways were related 
to the immune system (TGF-β, TNFR1, and TOB1 
pathways).26 In contrast, a more recent study integrat-
ing results across 5 different pathway analysis methods 
observed enrichment of TGF-β signaling after pooling 
GWAS results for major depressive disorder (9227 cases 
and 7383 controls), bipolar disorder (6990 cases and 
4820 controls), and schizophrenia (9379 cases and 7736 
controls) but no enrichment of immune pathways in 
schizophrenia alone.27 Thus, it remains unclear whether 
the immune disturbances apparent in schizophrenia are 
genetically mediated.
Here we directly tested the hypothesis that common 
variation within immune genes contributes to schizo-
phrenia in a total sample of 35 476 schizophrenia cases 
and 46 839 controls. We first evaluated the collective asso-
ciation and overall enrichment of SNPs within immune 
loci in schizophrenia to discern whether existing genetic 
data support an immunological cause of the disease. We 
then evaluated association of individual immune compo-
nents with schizophrenia to identify candidates driving 
the immune disturbances observed in the disease.
Subjects and Methods
Samples and Quality Control
An overview of GWAS datasets analyzed, including 
information about immune SNP coverage, is provided 
in table 1 and supplementary table 1. All analyses used 
imputed genotype dosages or summary statistics gener-
ated according to quality control and imputation proto-
cols described in the original GWASs.
Schizophrenia
We analyzed data from the most recent schizophrenia 
GWAS conducted by the PGC.2 The full dataset com-
prised 52 cohorts totaling 35 476 cases and 46 839 con-
trols, and was described in detail in the primary GWAS 
analysis.2 For analyses using individual-level SNP data, we 
analyzed the 36 European ancestry case–control cohorts 
for which we had ethics approval (25 629 cases and 30 976 
controls, see supplementary table 2 for details). For anal-
yses using summary statistics we used summary results 
generated as described in the primary analysis.2
Autoimmune Diseases
To evaluate the robustness of our approach to evaluate 
immune enrichment, and to benchmark our findings for 
Table 1. Description of Samples
Sample PMID Cases Controls Cohorts
Schizophrenia 25056061 35 476 46 839 52
Crohn’s disease 21102463 6333 15 056 6
Multiple sclerosis 21833088 9772 17 376 23
Psoriasis 20953190 2178 5 175 1
Rheumatoid arthritis 20453842 5539 20 169 6
Ulcerative colitis 21297633 6687 19 718 6
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schizophrenia, we analyzed GWAS summary statistics 
from 5 diseases of known immune origin: Crohn’s disease 
(6333 cases and 15 056 controls),28 multiple sclerosis (9772 
cases and 17 376 controls),29 psoriasis (2178 cases and 5175 
controls),30 rheumatoid arthritis (5539 cases and 20 169 
controls),31 and ulcerative colitis (6687 cases and 19 718 
controls).32 Multiple sclerosis, psoriasis, and rheumatoid 
arthritis have long been considered classic autoimmune 
diseases based on the presence of self-reactive immune 
cells, directed against a tissue-specific antigen. Crohn’s 
disease and ulcerative colitis have historically been con-
sidered inflammatory diseases, but recent genetic data 
also support an autoimmune component.33 For brevity, 
we refer to these 5 immune diseases of inflammatory and 
autoimmune origin as autoimmune throughout the article.
Access to the multiple sclerosis dataset29 was obtained 
with permission from the International Multiple Sclerosis 
Genetics Consortium (IMSGC). Access to the psoriasis 
GWAS dataset30 was obtained with permission from the 
Wellcome Trust Case Control Consortium (WTCCC), and 
imputed as described in Tsoi et al.34 The remaining autoim-
mune disease GWAS datasets were publicly available (see 
supplementary table 1 and Web Resources for details).
Gene Sets
Immune Gene Set. We defined immune genes as those with 
an immune response annotation in Kyoto Encyclopedia 
of Genes and Genomes (KEGG), Gene Ontology (GO), 
Ingenuity, and Immunology Database and Analysis Portal 
(ImmPort) as accessed on Sept 21, 2014 (for details, see 
supplementary table  3). We included autosomal genes 
present in 3 of the 4 databases in our immune gene set. 
We excluded immune genes encoded in the xMHC (chro-
mosome 6, 25–34 Mb), due to the broad association and 
extensive linkage disequilibrium (LD) in this region. All 
SNPs within the xMHC were also excluded from subse-
quent analyses.
Immune SNPs were defined as those falling within 
50 kb upstream or downstream2 of the transcribed region 
of genes in the immune gene list (973 genes representing 
145 Mb, see supplementary tables 1 and 4 for details of 
immune genes and SNP coverage).
Null Gene Set. To create the null gene set, we randomly 
selected 973 autosomal genes outside of the xMHC (rep-
resenting 150 Mb), resulting in a list containing the same 
number of genes as the immune gene set. Null SNPs were 
defined using a 50 kb gene window.
Brain Gene Set. We used the brain gene set identified and 
previously described by Raychaudhuri et al,35 with exclusion 
of those brain genes encoded within the xMHC. Briefly, 
brain genes were identified using 4 independent approaches: 
preferential gene expression in the brain compared to other 
tissues, neural-activity annotation by Panther, learning 
annotation in Ingenuity, and synapse annotation in Gene 
Ontology. Brain SNPs were defined using a 50 kb gene win-
dow (2635 genes representing 589 Mb).
Statistical Methods
Association of Immune Genes in Schizophrenia. To for-
mally evaluate statistical significance of the immune 
hypothesis of schizophrenia, we performed a joint associa-
tion analysis of all immune SNPs. This analysis included 
the 36 European ancestry case–control cohorts for which 
we had ethics approval (25 629 cases and 30 976 controls). 
Schizophrenia case status was permuted 100 times, an 
approach that created a null dataset while preserving the 
LD pattern between the 346 253 immune SNPs available 
for analysis. For each permutation, association testing 
for each immune SNP was performed by logistic regres-
sion separately in each cohort adjusting for ten multidi-
mensional scaling components (C1, C2, C3, C4, C5, C6, 
C7, C9, C15, C18), followed by inverse-variance weighted 
fixed effects meta-analysis. A sum of the Wald χ2 (1 degree 
of freedom) test statistics for immune SNPs was obtained, 
and the empirical P-value was calculated as the proportion 
of permutation samples whose sum statistic was larger than 
that in the observed sample. The same permutation analy-
sis was repeated for the null set of 290 239 SNPs within 973 
randomly selected genes as a baseline comparison.
Benchmarking Immune Involvement Using Stratified LD 
Score Regression. To benchmark genetically mediated 
immune involvement in schizophrenia, we applied strati-
fied LD Score regression, which partitions heritability into 
functional categories while adjusting for LD-induced cor-
relations and accepts summary statistics as input.36 This 
method leverages the relationship between LD and asso-
ciation test statistics to estimate the per-SNP heritability 
attributable to a functional category by multiple regression 
of the association test statistic (χ2) for SNP j against the 
LD Score of SNP j with respect to each functional cat-
egory. Briefly, the regression coefficients obtained by mul-
tiple regression correspond to category-specific per-SNP 
heritabilities (τc) that account for the effects of all other 
categories, and can be used to estimate category-specific 
enrichment of SNP-based heritability (h2SNP). Thus, strati-
fied LD Score regression identifies a functional category 
as enriched for heritability if SNPs with high LD to that 
category have higher association test statistics than SNPs 
with low LD to that category. The enrichment estimates 
are defined as the proportion of SNP heritability explained 
by a functional category, normalized to the proportion of 
SNPs in that functional category. The statistical frame-
work has been described in detail previously.36
To apply stratified LD Score regression we obtained 
summary statistics for 43 European-ancestry cohorts com-
prising the schizophrenia GWAS.36 We considered only 
the subset of SNPs with available summary statistics that 
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overlapped HapMap Project Phase 3 (HapMap3)37 SNPs 
(as a proxy for well-imputed SNPs), because stratified LD 
Score regression does not account for imperfect imputa-
tion. First, we calculated LD Scores for these HapMap3 
SNPs with respect to the immune and brain SNP catego-
ries, as well as a baseline gene category that included all 
SNPs within a 50 kb window of the transcribed region 
of any gene. Next, we estimated enrichment of herita-
bility for the immune and brain functional categories 
using a multiple linear regression model that included 
either the immune or brain annotations in addition to 54 
overlapping categories (our baseline gene category, and 
the 53 annotations previously described by Finucane36), 
because the accuracy of enrichment estimates is improved 
by including many functional categories in the model. 
Standard error estimates were obtained by block jackknif-
ing over 200 equally sized blocks of SNPs.36
Immune Candidate Gene Identification. To evaluate 
association of specific immune components with schizo-
phrenia, we used summary statistics from the complete 
PGC schizophrenia GWAS.2 Index SNPs, defined as the 
SNP with the smallest association P-value for each dis-
ease-associated locus and identified in the primary analy-
sis of the PGC dataset as previously described.2
Results
Immune Gene Set and Corresponding Immune SNPs
To define an inclusive immune gene set we used an anno-
tation-based approach which captured 973 autosomal 
immune genes, represented by a total of 587 933 SNPs 
in the schizophrenia GWAS (see supplementary table 4 
for details of SNP coverage for immune genes). Although 
there is a robust xMHC association in schizophrenia, 
there is extensive LD in this region which can bias stan-
dard enrichment approaches and lead to false-positive 
results.38 To avoid this bias, we excluded the xMHC from 
the main analyses, and focused on immune genes outside 
of this region. To substantiate that our approach did not 
exclude from investigation immune loci with a major role 
in schizophrenia, we fine-mapped the xMHC association 
in schizophrenia (supplementary methods). Concordant 
with previous reports,39,40 the primary signals in schizo-
phrenia captured by GWAS variants did not map to cod-
ing variants in the human leukocyte antigen (HLA) genes 
typically implicated in autoimmune disease. Instead, we 
found 3 independent xMHC associations in schizophrenia 
corresponding to SNPs that represented (1) an extended 
class I region association spanning ~2 Mb, (2) a class II 
region variant located near the C4 gene, concordant with 
the recent finding that C4 structural variants—requiring 
specialized imputation methods beyond standard GWAS 
analysis pipelines—are associated with schizophrenia,40 
and (3) the SYNGAP1 gene, in which de novo mutations 
have already been implicated in schizophrenia41 and other 
neurodevelopmental disorders42,43 (supplementary fig-
ure 1). Although we did not impute C4 structural variants 
in the present study, Sekar et al have previously reported 
that there is no remaining association in the class II region 
after adjusting for C4 variation in the PGC schizophre-
nia GWAS.40 Thus, despite previous interpretations of 
the xMHC association in schizophrenia representing an 
autoimmune cause of disease,22,24,25 we found no evidence 
for involvement of the HLA genes typically driving auto-
immune susceptibility. We cannot disprove that genetic 
variation in the MHC may influence schizophrenia sus-
ceptibility via additional independent variants that did 
not reach significance in the present analysis, or underly-
ing causal variants that were not captured in the current 
GWAS. Nevertheless, our findings suggest that our focus 
on immune genes outside of the xMHC was unlikely to 
have excluded from investigation common immune vari-
ants captured in the current GWAS that have a major role 
in schizophrenia.
Evaluating Collective Association of Immune Genes in 
Schizophrenia
To determine whether current genetic data support an 
immune cause of schizophrenia, we first evaluated the 
summed association signal from genes encoding immune 
components using individual-level SNP data from the 
largest GWAS currently available2 (25 629 cases and 30 976 
controls of European ancestry). We observed evidence 
of inflation of the summed association test statistics for 
immune loci in schizophrenia (λimmune  =  1.48, empirical 
P < .01, figure  1), suggesting potential involvement of 
immune pathways in disease etiology. Given the substan-
tial polygenic contribution to schizophrenia, some degree 
of inflation is expected even among a randomly selected 
set of SNPs.2 To determine whether the collective associa-
tion of immune SNPs exceeded that expected given the 
polygenic architecture of schizophrenia, we repeated the 
permutation analysis on a set of 973 randomly selected 
autosomal genes representing approximately the same 
proportion of SNPs as our immune gene set. We observed 
greater inflation of the summed association test statistic 
for this null gene set (λnull = 1.54, empirical P < .01, fig-
ure 1), suggesting the collective association observed for 
immune SNPs was driven by the polygenicity of schizo-
phrenia rather than specific involvement of immune loci 
in the disease.
Benchmarking Contribution of Immune Genes to 
Schizophrenia
To benchmark genetically mediated immune pathway 
involvement, we quantified enrichment of heritability 
among immune SNPs compared to SNPs in the rest of 
the genome in schizophrenia and 5 diseases of known 
immune origin (Crohn’s disease,28 multiple sclerosis,29 pso-
riasis,30 rheumatoid arthritis,31 and ulcerative colitis32). We 
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estimated enrichment of immune SNPs using the recently 
developed stratified LD Score regression approach,36 
which uses multiple linear regression of χ2 test statistics 
against LD Score with respect to functional categories 
to estimate category-specific enrichment of SNP-based 
heritability (h2SNP). As expected based on previous litera-
ture and known biology, immune genes were consistently 
enriched 2- to 8-fold for h2SNP across all 5 autoimmune 
diseases (P < 5 × 10−3, figure 2 and table 2). In contrast 
to our findings in autoimmune diseases, immune genes 
were not enriched for heritability in schizophrenia 
(P =  .94, figure 2 and table 2). As a separate approach 
we applied stratified false discovery rate (sFDR) control44 
to obtain enrichment estimates for immune genes, and 
again observed immune enrichment across the 5 autoim-
mune diseases but not schizophrenia (supplementary fig-
ure 2 and supplementary methods). Taken together, these 
results suggest that immune genes as a group may not be 
major drivers of schizophrenia risk.
It is possible that we were unable to detect true immune 
enrichment in schizophrenia due to its unique genetic 
and clinical architecture (highly polygenic and clinically 
heterogeneous) relative to the autoimmune diseases ana-
lyzed. As a positive control, we applied stratified LD Score 
regression to quantify enrichment of a set of brain genes 
previously reported to be enriched for schizophrenia her-
itability.45 As expected, we observed significant enrich-
ment of brain genes in schizophrenia (P  =  1.14 × 10−14, 
figure 2 and table 2), indicating that we are able to detect 
true pathway enrichment in schizophrenia despite the 
high degree of polygenicity and clinical heterogeneity.
Identification of Immune Candidates Individually 
Associated With Schizophrenia
Although we found no overall enrichment of immune 
loci in schizophrenia, we hypothesized that individual 
immune genes may be implicated in the disease. Of the 
108 previously reported loci associated with schizophre-
nia,2 we identified 6 independent regions on chromo-
somes 2, 5, 8, 11, and 16 where the index SNP was an 
immune SNP (table  3, supplementary figure  3). To the 
best of our knowledge, none of these loci, which rep-
resented the DPP4, HSPD1, EGR1, CLU, ESAM, and 
NFATC3 genes, have been previously associated with an 
autoimmune disease. All 6 of the immune genes associ-
ated with schizophrenia are expressed in human brain 
tissue46 (supplementary figure 4). Interestingly, their pro-
tein products have roles in immune cell activation and 
adhesion, as well as established roles in the brain such 
as regulating myelination (HSPD1),47 synaptic plasticity 

































Fig. 2. Estimated enrichment for immune (red) and brain (blue) 
genes in schizophrenia and 5 autoimmune diseases. The y-axis 
represents estimated enrichment for each gene set, defined as the 
proportion of heritability explained divided by the proportion 
of SNPs for that gene set. Values >1 (dotted line) indicate 
enrichment of heritability. Error bars represent enrichment 
estimates ± standard error. ***P < 1 × 10−5, **P < 1 × 10−3, *P 
< .01 in a test of whether the estimated enrichment was equal to 
one. CRO, Crohn’s disease; MS, multiple sclerosis; PSO, psoriasis; 
RA, rheumatoid arthritis; SCZ, schizophrenia; UC, ulcerative 
colitis.
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(EGR1),48 blood–brain barrier permeability (ESAM),49 
and neuronal loss after brain injury (NFATC3,50 CLU51).
Discussion
The hypothesis that schizophrenia may be an immuno-
logical disease is longstanding.3–5 Using the largest col-
lection of genetic data currently available, we evaluated 
the immune hypothesis of schizophrenia empirically. We 
have shown that common variation at immune genes pres-
ents a very different genetic architecture in schizophrenia 
as compared to diseases of known immune origin. First, 
the collective association of non-MHC immune genes in 
schizophrenia was not greater than expected given the 
polygenic architecture of the disease. Second, there was 
no enrichment of heritability among non-MHC immune 
genes in schizophrenia, in contrast to that observed 
in autoimmune diseases. While broad immune enrich-
ment—or enrichment of specific immune pathways such 
as TGF-β signaling, which has already been observed 
when pooling GWAS results across all major adult psy-
chiatric disorders27—may be detected as GWAS sample 
sizes increase further, our benchmarking establishes that 
the degree of enrichment in schizophrenia is substantially 
less than that seen in autoimmune diseases. Third, the 
immune loci that were individually associated with schizo-
phrenia had important alternate roles in brain develop-
ment and homeostasis, raising the possibility that proteins 
with dual immune-neural function are responsible for the 
link between schizophrenia and the immune system. For 
instance, ESAM regulates blood–brain barrier permeabil-
ity,49 and may influence susceptibility to schizophrenia by 
regulating exposure to the peripheral immune milieu. As 
samples available for genetic study increase in size and 
new genotyping approaches emerge, additional immune 
genes robustly associated with schizophrenia are likely to 
be discovered, and it will be critical to evaluate how these 
immune components may act in the brain.
Our methodological approach was subject to several 
important limitations. First, the immune gene list was 
broad, which may have diluted any enrichment in a more 
specific immune subset or pathway. Second, our anno-
tation-based approach to defining the immune gene list 
did not capture remote regulatory regions for immune 
Table 3. Genome-Wide Significant Immune Genes in Schizophrenia
SNP Chr Position OR (95% CI) P Gene Locationa
rs2909457 2 162845855 0.94 (0.92–0.96) 4.38 × 10−8 DPP4 +2.9 kb
rs6434928 2 198304577 0.93 (0.91–0.95) 1.48 × 10−11 HSPD1 +46.7 kb
rs3849046 5 137851192 1.06 (1.04–1.08) 4.83 × 10−9 EGR1 Intronic
rs73229090 8 27442127 0.91 (0.88–0.94) 1.95 × 10−8 CLU +12.3 kb
rs55661361 11 124613957 0.92 (0.90–0.94) 3.68 × 10−12 ESAM +9.1 kb
rs8044995 16 68189340 1.08 (1.05–1.11) 3.27 × 10−8 NFATC3 Intronic
aLocation relative to immune gene of interest; +, downstream. SNP, single nucleotide polymorphism.
Table 2. Enrichment and Per-SNP Heritability Estimates for Immune and Brain Gene Sets
Disease h2 enrichment SE P per-SNP h2 (τc) SE P
Immune gene set
 Schizophrenia 1.01 0.15 .94 −7.01 × 10−9 1.11 × 10−8 .53
 Crohn’s disease 4.54 0.66 6.80 × 10−8 2.04 × 10−7 6.28 × 10−8 1.16 × 10−3
 Multiple sclerosis 8.56 1.60 2.16 × 10−6 1.49 × 10−7 2.84 × 10−8 1.55 × 10−7
 Psoriasis 7.08 1.97 2.00 × 10−3 2.26 × 10−7 7.17 × 10−8 1.62 × 10−3
 Rheumatoid arthritis 5.18 0.87 1.41 × 10−6 1.01 × 10−7 2.70 × 10−8 1.83 × 10−4
 Ulcerative colitis 6.38 0.93 7.36 × 10−9 1.87 × 10−7 3.68 × 10−8 3.74 × 10−7
Brain gene set
 Schizophrenia 1.76 0.10 1.14 × 10−14 4.04 × 10−8 9.24 × 10−9 1.23 × 10−5
 Crohn’s disease 0.69 0.15 .04 −1.54 × 10−8 2.20 × 10−8 .48
 Multiple sclerosis 0.14 0.31 4.84 × 10−3 −1.27 × 10−8 1.11 × 10−8 .25
 Psoriasis 0.42 0.53 .27 −6.30 × 10−9 3.29 × 10−8 .85
 Rheumatoid arthritis 0.85 0.29 .61 −4.61 × 10−10 1.21 × 10−8 .97
 Ulcerative colitis 0.62 0.24 .11 −2.49 × 10−9 1.32 × 10−8 .85
Note: Bold font indicates those SNP sets that are enriched based on both enrichment estimates and per-SNP h2 estimates (τc). τc 
estimates are obtained using a multivariate model that includes all other functional categories whereas the enrichment estimates only 
consider the functional category of interest. Therefore, when the enrichment estimate is significant without a significant τc estimate, this 
suggests the result may be driven by correlation with other functional categories. SNP, single nucleotide polymorphism.
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genes. Third, the MHC region was excluded from all 
analyses subsequent to fine-mapping the MHC associa-
tion. Due to extensive LD in the MHC region, current 
approaches for gene-enrichment analysis are not robust to 
inclusion of MHC variants and this is an important area 
of future methods development. Fourth, schizophrenia 
is an umbrella diagnosis that, like other complex disor-
ders, likely captures many distinct molecular subtypes.52 
Thus, the broad phenotype classification used to define 
the patient cohort in the present study likely resulted in 
clinical heterogeneity within our sample. As immune dis-
turbances may be causal in only a subset of schizophrenia 
patients, this clinical heterogeneity may have diluted asso-
ciation signals in the immune gene set. Fifth, our study was 
limited to common variants captured by current GWASs, 
which do not account completely for the estimated heri-
tability of schizophrenia.53 Finally, given evidence that 
exposure to inflammatory mediators in utero increases the 
risk of schizophrenia,54 it may be maternal immune varia-
tion that contributes to the immune disturbances seen in 
patients with schizophrenia. Given these limitations, we 
cannot completely exclude a potential genetic etiology for 
the immune disturbances observed in schizophrenia.
Despite these limitations, to the best of our knowl-
edge, this was the most comprehensive investigation of the 
hypothesis that immune genes contribute to schizophre-
nia. Based on current GWAS data, schizophrenia does not 
appear to be an autoimmune disease per se, although there 
may be modest contributions to genetic susceptibility from 
a specific subset of immune genes with additional roles out-
side of immunity (for example, neurodevelopmental). Our 
findings also raise the possibility that the immune distur-
bances observed in schizophrenia are of nongenetic etiol-
ogy. Importantly, we cannot exclude the possible causal role 
of environmental risk factors that activate or “prime” the 
immune response (eg, infections, stress) in schizophrenia. 
Alternatively, the immune disturbances seen in schizophre-
nia may be a downstream factor in disease pathogenesis, 
fueling progression or modifying disease outcomes rather 
than initiating the disease. Finally, the immune changes 
observed in schizophrenia may simply be a byproduct of 
disease pathogenesis or patient lifestyle factors (ie, antipsy-
chotic medication, smoking, and diet). Whether the immune 
abnormalities accompanying schizophrenia are causal, dis-
ease modifying, or epiphenomena is an important question 
to be addressed by longitudinal studies, particularly given 
burgeoning interest in potential immunotherapies.
Web Resources
 • Summary statistics:
 • Schizophrenia2: http://www.med.unc.edu/pgc/files/
resultfiles/scz2.snp.results.txt.gz%20%20. Accessed 
May 4, 2016.
 • Crohn’s disease28: ftp://ftp.sanger.ac.uk/pub4/ibdge-
netics/cd-meta.txt.gz. Accessed May 4, 2016.
 • Rheumatoid arthritis31: http://www.broadinstitute.org/
ftp/pub/rheumatoid_arthritis/Stahl_etal_2010NG/. 
Accessed May 4, 2016.
 • Ulcerative colitis32: ftp://ftp.sanger.ac.uk/pub4/ibd-
genetics/ucmeta-sumstats.txt.gz. Accessed May 4, 
2016.
 • Stratified LD Score regression software36: github.com/
bulik/ldsc. Accessed May 4, 2016.
 • sFDR software44: http://www.utstat.toronto.edu/sun/
Software/SFDR. Accessed May 4, 2016.
Supplementary Material
Supplementary material is available at http://schizophre-
niabulletin.oxfordjournals.org.
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